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H 
uman autoimmune diseases have a striking genetic as- 
sociation with particular alleles of major histocompati- 
bility  complex (MHC)  class  I  or II genes.  The field was 
established  by  the  seminal  discovery of HLA-B27-1inked 
susceptibility to ankylosing spondylitis, a chronic inflammatory 
joint disease (1, 2). MHC-associated susceptibility has now 
been documented for a variety of human autoimmune diseases, 
including insulin-dependent diabetes meUitus (IDDM), rheu- 
matoid arthritis  (RA),  pemphigus vulgaris (PV),  multiple 
sclerosis,  and myasthenia gravis, just to name a few (3-8). 
A genome-wide search for diabetes susceptibility genes using 
microsatellite markers has demonstrated that several  genes 
contribute to the disease process, but that the MHC is the 
most important susceptibility locus (9). Despite this remark- 
able progress, several critical questions remain to be answered 
to establish a causal relationship between the genetics and 
the immunopathogenesis: (a) Is the role of MHC molecules 
in autoimmunity based on the presentation of (self) peptides? 
(b) What is the biochemical nature of these peptides? (c) Are 
these peptides specific for a particular disease associated MHC 
molecule and the target organ of the immune attack? (d) What 
mechanisms induce an autoaggressive T cell response to these 
self determinants? 
Recent developments in the field, particularly the structural 
characterization of MHC-peptide complexes and the identi- 
fication of allele-specific peptide-binding motifs, have trans- 
formed the field (10-13). Based on this knowledge, the struc- 
tural basis  for MHC-linked  susceptibility to autoimmune 
diseases can be reassessed at a level of detail sufficient for solving 
longstanding questions in the field. Motifs for peptide binding 
to MHC class I and II molecules were defined by sequence 
analysis of naturally processed peptides and by mutational 
analysis of known epitopes. MHC class I-bound peptides were 
found to be short (generally 8-10 amino acids long) and to 
possess two dominant MHC  anchor residues; MHC  class 
II-bound peptides were found to be longer and more hetero- 
geneous in size (10-17). The size heterogeneity has made it 
more difficult to define MHC class II-binding motifs based 
on sequence alignments; the crystal structure of HLA-DK1 
has, however, clearly demonstrated that there is a dominant 
hydrophobic anchor residue close to the NHz  terminus of 
the peptide, and that secondary anchor residues are found 
at  several other peptide positions (13,  15,  18). 
The peptide-binding site of human HLA-DK molecules 
is generated by the first domains of the conserved DKot and 
the  polymorphic DK/$  chain.  A  prominent  hydrophobic 
pocket that is highly conserved between human DR. molecules 
accommodates the primary anchor residue. Most residues that 
shape this pocket are from the DR.or chain; however, the size 
of this pocket is controlled by the Val/Gly dimorphism at 
position 86 of the DR,8 chain (15, 18). When glycine is present 
at  DKB86,  aliphatic or  aromatic  residues can  anchor  the 
peptide; with valine at DRB86, the pocket is smaller so that 
tyrosine and tryptophan cannot be accommodated (13,  19). 
In the HLA-DK1 structure, shallower pockets accommodate 
other peptide side chains, particularly side chains of P4, P6, 
P7, and P9 (relative to the first anchor Pl). Peptide residues 
at these positions appear to contribute to the specificity of 
peptide binding to different DR molecules (13). 
The fact that both the primary pocket and the hydrogen 
bonding network along the peptide main chain are highly 
conserved among different DR` molecules accounts for the 
fact that a number of high affinity peptides bind to a number 
of different DR molecules ("promiscuous" binding) (13, 17, 
20).  How can this observation be reconciled with the hy- 
pothesis that the association of different class II alleles is based 
on selective peptide binding to the disease-associated mole- 
cules? The answer to this question, which is the focus of 
this review, relates to the following facts: (a) Selective and 
nonselective peptides have been identified (17, 20). (b) Charged 
residues at two key positions in the class II/3 chain (positions 
/$71 and/$57) control the charge permitted at peptide posi- 
tion P4 (~71) and P9 (/$57)  (for positioning of P4 and P9 
in HLA-DR. pockets see reference 13). (c) Nonselective pep- 
tides do not carry a charge at these positions (P4 or P9). (d) 
Peptides with charged residues at P4 and/or P9 can only bind 
if an opposing charge (or no charge) is present at the respec- 
tive position in the MHC  dass II/$ chain (21). 
A large body of epidemiological work has documented the 
association  of RA  with  the  following DR.  alleles:  DR.4 
(DRBI*0401,  DRBI*0404)  and DR1 (DRBI*0101),  with 
the DR,4 alleles conferring a higher risk than DR.I (22). The 
risk is dramatically increased when the subject is homozy- 
gous or heterozygous for DRBI*0401 and/or DRBI*IM04. 
The importance of DR4 in the development of arthritis is 
also underscored by the  following observations:  The vast 
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of arthritis (Felty's syndrome), which is associated with spleno- 
megaly  and  high  titers  of rheumatoid  factor,  carry  the 
DRBI*0401 allele (23). DR4 is also associated with chronic 
arthritis in patients with Lyme disease since the presence of 
DR.4 significantly prolongs the clinical duration of arthritis 
after infection with Borrelia burgdorferi (24). The observation 
that arthritis is associated with three DR alleles that are struc- 
turally similar led to the development of the "shared epitope" 
hypothesis since DRBI*0401,  0404  and 0101 share critical 
polymorphic residues  in the DK B67-71  cluster (L--QK) 
(Table 1) (22).  These residues  (particularly DRB71) appear 
to be critical in defining the selectivity of peptide binding 
to the disease-associated  molecules. 
The paper by Hammer et al. in this issue (21) compares 
the requirements for selective binding to these DR4 subtypes, 
particularly  between  DRBI*0404  (RA  associated)  and 
DRBI*0402 (not RA associated),  which differ only in the 
DK~67-71 region. Using the random peptide library in bac- 
teriophage that they had previously developed,  both mole- 
cules were found to have identical requirements at the pri- 
mary anchor residue P1 (aliphatic amino acids or phenylalanine, 
corresponding to DtL886 Val) and at P6 (preference for Ser, 
Thr, Ash, or Val) (25).  However, requirements for peptide 
binding were dramatically different for peptide position 4. 
Peptides with a negative charge at P4 bound to DRBI*0404 
(RA associated), but not to DRBI*0402; the reverse was true 
for peptides with a positive charge at P4. Site-directed muta- 
genesis demonstrated that DRB71 was responsible  for this 
effect: peptides with a negative charge at P4 were selective 
for DRBI*0404, which has a positive charge at DRB71 (Arg), 
while peptides with a positive charge at P4 were selective 
for DRBI*0402, which has a negative charge at DRy71 (Glu). 
The authors used these criteria to search among candidate 
antigens for RA (link protein, collagen, heat shock protein 
65, and fillagrin) for peptides that may have selective binding 
for the KA-associated DK4 subtype, and they identified 14 
peptides from these candidate antigens (25). 
Based on these observations and on the extensive  work 
carried out to define MHC class II peptide-binding motifs, 
we would like to propose a model to explain the linkage of 
human autoimmune diseases to particular MHC class II genes. 
The model is based on the fact that two different autoim- 
mune diseases, RA and PV, are linked to DR4 subtypes that 
differ only in the DR~67-71 cluster (4, 5, 26). PV is an au- 
toimmune disease of the skin in which high titer autoanti- 
body production to an epidermal cell adhesion molecule (des- 
moglein  3)  results  in  a  loss  of  keratinocyte  adhesion 
(acantholysis) and subsequent severe blister formation (27). 
In different ethnic groups, the disease is associated either with 
Table  1.  Selectivity of Peptide Binding to DR4 Antigens  Associated with l~'fferent Autoimmune  Diseases: Structural Criteria for 
Candidate Peptides in PV and RA 
PV  RA 
Disease-associated DR4 molecule 
Polymorphic DtL8 chain residues at 
DRB 67, 70, 71,  86 
Charge  at DRB71 
Charge at peptide position 4 
Criteria  for selective peptides 
Autoantigen 
T cell response 
Pathogenetic mechanism 
Clinical manifestations 
DRBI'0402 
I,  D, E,  V 
Negative  (E) 
Positive  (K or R) 
Pl: V, L, I, M, F 
P4:  K,  R 
P6: S, T, N, V 
Epidermal adhesion molecule 
(Desmoglein 3) 
TH2 
Autoantibodies 
Loss of epidermal cell adhesion, 
severe blister formation 
DRBI'0401,  DRBI*0404 
L, Q, R, V (0404) 
L, Q, _R, G (0401) 
Positive  (_g) 
Negative  (D or E) 
PI:V, L, I, M, F 
P4:  D,  E 
P6:S,  T, N, V 
Unknown 
TH1 
T cell mediated 
Joint inflammation 
Immunological  and clinical  characteristics of DR4-associated autoimmune  diseases, PV, and RA. In pemphigus, autoantibody  formation  to an epider- 
mal adhesion molecule results in blister formation; in rheumatoid arthritis, T cells are thought to induce a chronic inflammatory  reaction of the 
joint synovia  that results in cartilage destruction. Pemphigus and RA are associated with DR4 subtypes that differ  only  in the polymorphic  DP~ 
67-71 cluster  on the DRB chain helix. Of these residues, DRB 71 is critical in defining  which peptides will bind selectively  to either the pemphigus- 
or the RA-associated  DR4 molecule. In the pemphigus-associated  DRBl*0402 molecule, DRB71 is negatively  charged; in the arthritis associated 
DKBI"0401 and 0404 molecules, it is positively  charged. The reverse charge is found at peptide position P4: peptides selective  for the pemphigus 
DRB1"0402 molecule  have a positive  charge at P4, while  a negative  charge is found  at P4 for peptides selective  for the KA-associated  DR4 molecules. 
Based on these data motifs for selective binding of peptides to either PV- or RA-associated  DR4 molecules can be defined. 
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(DQB1*05032);  only a small fraction of PV patients have 
neither susceptibility gene (4, 5, 28, 29). The DR4 subtype 
associated with pemphigus differs only at three positions, all 
in the DK~67-71 cluster,  from the DR4 subtype associated 
with RA. The PV-associated molecule has a negative charge 
(Glu) at the critical position (DRB71); the neighboring posi- 
tion (DRy70) is also negatively charged. The Dlk4 subtype 
associated  with PV is the only one that carries  a negative 
charge at DRB71, a positive charge (Arg) is found at DRB71 
in the RA-associated DR4 molecules. DRB67 (Leu, Ile) does 
not appear  to be involved in peptide binding and probably 
acts  as a TCK contact residue (13, 30). 
The charge of a polymorphic residue at DP,  g71 could there- 
fore account for susceptibility to two different autoimmune 
syndromes associated with structurally similar DR4 subtypes 
(Table 1). DR4 alleles associated with susceptibility to RA 
have a positive charge at DR/571 (Arg), while the DR4 al- 
lele associated with PV has a negative charge at DR/571 (Glu). 
Peptides selective for either DR4 molecule may therefore differ 
significantly in their charge at P4: Peptides with a negative 
charge at P4 would be expected to bind to the RA-associated 
molecules, but not the pemphigus-associated DR4 molecule; 
in contrast, a positive charge would be expected for the pem- 
phigus peptide(s)  at position 4 (Table 1). Because of the con- 
served nature of these molecules, other peptide anchor residues 
(P1 and P6) would not be expected to be different for these 
DR4  subtypes. 
This model now allows the prediction of T cell epitopes 
of a known autoantigen that are selectively presented by the 
disease-associated  MHC molecule (Table 2).  The existence 
of self peptides that are indeed selectively presented by the 
disease-associated molecule and are the target of autoreactive 
DR4-associated  Autoimmune  Diseases 
DR~ 71  P4 
Rheumatoid Arthritis  Arg  Asp, Glu 
Pemphigus  Glu  Lys, Arg 
DQ-associated  Autoimmune  Diseases 
Table  2.  Candidate Peptides for PV: Desmoglein 3 Peptides 
That Match the DRB1 *0402 Binding Motif 
Motif  1  4  6 
PVA.1 (res. 78-93) 
PVA.2 (res. 97-111) 
PVA.3 (res. 190-204) 
PVA.4 (res. 206-220) 
PVA.5 (res. 251-265) 
PVA.6 (res. 512-526) 
PVA.7 (res. 762-786) 
V  KS 
L  RT 
I  N 
M  V 
F 
ATQKITYRISGVGID 
FGIFVVDKNTGDINI 
LNSKIAFKIVSQEPA 
TPMFLLSRNTGEVRT 
CECNIKVKDVNDNFP 
SARTLNNRYTGPYTF 
QSGTMRTRHSTGGTN 
The DKBI*0402 motif was used to define  peptides of the autoantigen 
desmoglein  3 that may  bind selectively  to the disease-associated  DRBI*0402 
molecule. Seven  peptides from this large protein (999 amino acids) were 
found to match the motif. T cell recognition  of one (or several) of these 
peptides may initiate the autoimmune  process in pemphigus, res, residues. 
DQ[5 57  P9 
Diabetes  Val  Asp, Glu 
Pemphigus  Asp  Lys, Arg 
Figure 1.  Polymorphic  MHC class II residues  critical  for peptide  binding 
are associated  with different  human autoimmune  diseases. An c~ carbon 
diagram of the peptide-binding  cleft of an HLA-DR molecule  (13, 15) 
is shown  with a peptide in the site. Among  the DR4 associated  diseases, 
the charge at position  DR/$71 controls the charge found  at peptide posi- 
tion P4 (relative  to the first MHC anchor, residue  P1). For DQ-associated 
autoimmune diseases, the charge at DQ/~57 is important. The fact that 
residues critical for selective  peptide  binding  are associated  with suscepti- 
bility to autoimmune  diseases indicates that MHC-linked susceptibility 
is almost certainly  caused  by the presentation  of (self) peptides that acti- 
vate autoaggressive  T cells. 
T  cells would explain the genetic association of the disease 
with the MHC. The target antigen of pemphigus vulgaris 
is an epithelial adhesion molecule of the cadherin family (des- 
moglein 3)  (27).  Desmoglein 3 mediates Ca + +-dependent 
adhesion between keratinocytes; the autoantibodies interfere 
with cell adhesion with resulting blister formation (31). The 
autoantibodies are thought to be pathogenic since a transient 
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a condition caused by the transfer of maternal immunoglob- 
ulin to the fetus. Transfer of serum- or desmoglein 3-specific 
antibodies to mice also results in acantholysis (32). 
The criteria for selective DRBl*0402-binding were there- 
fore used to localize candidate T cell epitopes of desmoglein 
3 (Table 2). For P1 and P6, the by now weU-defined anchor 
residues (PI: Val, Leu, Ile, Met, and Phe; P6: Ser, Thr, Asn, 
or Val) were used; for P4 only positively charged residues 
(Lys, Arg) were considered. Only seven peptides from this 
large protein (130 kD, 999 amino acids) matched the motif. 
Selective presentation of one or several of these peptides by 
the PV-associated  DRBI*0402  molecule to T  cells may be 
critical for initiating autoimmunity in PV. 
The model that charge-charge interactions between poly- 
morphic MHC class II molecules and peptides are critical in 
selective peptide binding and therefore in autoimmunity can 
be taken one step further (Fig. 1). In a different ethnic group, 
PV is associated with a rare DQ1  subtype (DQBl*05032) 
that differs from the common DQ1 subtype only at position 
57 of the DQ~ chain (29).  In the PV-associated  molecule, 
DQ~57 is negatively charged (Asp); in the common DQ1 
subtype, it is not. The same position on the DQ~ chain has 
also been implicated in susceptibility to diabetes.  In diabetes, 
however, the reverse is true: DQ2 and DQ8 molecules as- 
sociated with susceptibility to diabetes do not have a nega- 
tive charge at DQB57  (3). 
Based on these observations, it becomes clear that two poly- 
morphic positions in the MHC class II B chain (position 71 
of DRB and position 57 of DQ~) are critical for selective 
peptide binding and the development of autoimmunity. Based 
on the criteria described above, a diabetes-linked peptide would 
be expected to have a negative charge at P9 since such a pep- 
tide would only bind to DQ molecules that do not have the 
same charge at DQB57. In contrast, for the DQl-associated 
cases of pemphigus, a peptide with a positive charge at P9 
may be selective for the disease-associated  molecule that car- 
ries a negative charge at DQB57. In the case of DR4-linked 
autoimmunity, the charge at peptide position 4 confers selec- 
tivity to the disease-associated  DR4 molecule: RA peptides 
have a negative charge at P4, PV peptides a positive charge 
at P4. Motifs for selective peptide binding may therefore prove 
to be tremendously useful in the identification of key epi- 
topes that initiate human autoimmune diseases. This approach 
may not only be useful for identifying peptides in PV, RA, 
or diabetes,  but also for other autoimmune diseases where 
residues critical in peptide binding have been linked to dis- 
ease susceptibility. 
The observation that  single amino acid substitutions in 
the peptide-binding site of MHC class II molecules appear 
to be responsible for MHC-linked susceptibility to autoim- 
munity poses an interesting question: why are the resulting 
autoimmune syndromes so different in terms of their tissue 
localization and the immunological effector mechanisms? In 
pemphigus, autoantibodies induce a blistering disease of the 
skin; in RA, T cells mediate a chronic inflammatory process 
that results in cartilage destruction. The immunological at- 
tack may be primarily dictated by resident antigen presenting 
cells in the target organ:  skin keratinocytes or Langerhans 
cells may primarily induce a TH2-mediated T cell response 
with resulting autoantibody production, while APC in the 
synovia may trigger a THl-like T cell response and a chronic 
inflammatory state.  Selection of tissue-specific  self-peptides 
by disease-associated  MHC molecules may therefore decide 
between these different fates. 
Peptide motifs for MHC class II binding and T cell receptor 
for antigen recognition are also crucial for the identification 
of viral and bacterial peptides that mimic critical structural 
features of immunodominant self peptides and activate an- 
toaggressive T cells. This approach was successfully used to 
identify  viral  and  bacterial  mimicry peptides  of an  im- 
munodominant myelin basic protein peptide (residues 85-99). 
These mimicry peptides were derived from common human 
pathogens,  such as  influenza type A  virus,  human papil- 
lomavirus, Epstein-Barr virus, and herpes simplex type 1 virus, 
and they efficiently activated MBP-specific T cell clones from 
multiple sclerosis patients  (33). 
The elegant work by Hammer and co-workers, as well as 
that by many other laboratories in defining the structural basis 
of MHC class II-restricted peptide presentation, allows  us 
to probe some of the fundamental questions in autoimmu- 
nity. With respect to questions addressed in the opening re- 
marks, the following working hypotheses can be formulated: 
(a) The association of particular MHC alleles with autoim- 
mune syndromes is almost certainly caused by the presenta- 
tion of peptides as polymorphic residues critical in peptide 
binding are associated with susceptibility. (b) Peptides selec- 
tive for the disease-associated molecules can be identified using 
structural motifs that consider the charge-charge interactions 
at critical MHC-peptide interaction points (21).  (c) Struc- 
tural motifs for MHC binding and for T cell receptor recog- 
nition of important T  cell epitopes can be used to identify 
viral and bacterial mimicry peptides that have sufficient struc- 
tural similarity with immunodominant self peptides to ini- 
tiate the activation and clonal expansion of autoaggressive 
T  lymphocytes (33). 
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